A detailed history of China Universal Asset Management Co., Ltd. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 23,910 shares of ARWR stock, worth $511,913. This represents 0.05% of its overall portfolio holdings.

Number of Shares
23,910
Previous 14,592 63.86%
Holding current value
$511,913
Previous $379,000 21.9%
% of portfolio
0.05%
Previous 0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$19.36 - $29.54 $180,396 - $275,253
9,318 Added 63.86%
23,910 $462,000
Q2 2024

Jul 19, 2024

SELL
$21.87 - $28.24 $202,210 - $261,107
-9,246 Reduced 38.79%
14,592 $379,000
Q1 2024

Apr 29, 2024

BUY
$27.21 - $39.48 $310,438 - $450,427
11,409 Added 91.79%
23,838 $682,000
Q4 2023

May 21, 2024

SELL
$21.2 - $31.03 $241,870 - $354,021
-11,409 Reduced 47.86%
12,429 $380,000
Q4 2023

Jan 23, 2024

BUY
$21.2 - $31.03 $205,131 - $300,246
9,676 Added 351.47%
12,429 $380,000
Q3 2023

May 21, 2024

BUY
$26.2 - $36.08 $35,422 - $48,780
1,352 Added 96.5%
2,753 $73,000
Q3 2023

Oct 30, 2023

BUY
$26.2 - $36.08 $35,422 - $48,780
1,352 Added 96.5%
2,753 $74,000
Q2 2023

May 21, 2024

SELL
$25.16 - $41.38 $1,660 - $2,731
-66 Reduced 4.5%
1,401 $49,000
Q2 2023

Jul 27, 2023

SELL
$25.16 - $41.38 $1,660 - $2,731
-66 Reduced 4.5%
1,401 $50,000
Q1 2023

May 21, 2024

BUY
$23.68 - $38.51 $9,235 - $15,018
390 Added 36.21%
1,467 $37,000
Q1 2023

Apr 27, 2023

BUY
$23.68 - $38.51 $9,235 - $15,018
390 Added 36.21%
1,467 $37,000
Q4 2022

May 21, 2024

SELL
$28.0 - $40.56 $637,308 - $923,186
-22,761 Reduced 95.48%
1,077 $43,000
Q4 2022

Jan 31, 2023

BUY
$28.0 - $40.56 $2,380 - $3,447
85 Added 8.57%
1,077 $44,000
Q3 2022

Oct 21, 2022

BUY
$29.63 - $48.31 $29,392 - $47,923
992 New
992 $33,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.27B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.